Background: In arrhythmogenic cardiomyopathy ventricular fibrillation can be the first manifestation of the disease (primary VF). As an interaction between arrhythmogenic cardiomyopathy and Brugada syndrome with regard to the so-called connexome is possible the hypothesis is that primary ventricular fibrillation belongs to Brugada syndrome and later progresses to arrhythmogenic cardiomyopathy.

Method: A collective of 404 patients with arrhythmogenic cardiomyopathy were investigated to answer the question how many patients have right precordial ST-segment elevation in primary or in rare cases - secondary ventricular fibrillation.

Results: 9/14 patients had primary ventricular fibrillation and 2/9 patients (15 males, mean age 43.3 ± 9.6 years) had secondary ventricular fibrillation with had non-significant (< 2mm) coved-type ST elevation, Brugada type II ECG or atypical ST elevation in right precordial leads. Ajmaline challenge was not done in any case. In this cohort of patients coved-type or atypical right precordial ST-segment elevation was statistically significant (p < 0.005) for the development of ventricular fibrillation.

Conclusion: II seems that the so-called connexome is a relevant finding to predict ventricular fibrillation as the first manifestation of the disease with insignificant coved-type or atypical right precordial ST elevation.

Although a large volume of evidence supporting the use of dual antiplatelet therapy in patients with the acute coronary syndrome, there remains major uncertainty regarding the optimal duration of treatment. Clinical trials have varied markedly in the length of treatment. Some systematic reviews and meta-analyses assert that shorter durations of dual antiplatelet therapy are superior because the avoidance of thrombotic events is counterbalanced by the greater risks of significant excess bleeding with definite enhances in all-cause mortality with longer durations. These findings did not demonstrate remarkable heterogeneity according to whether patients had coronary artery disease. Therefore, the potential damages and benefits may differ when applied to the broad patients met in clinical practice who have notably higher complication rates. Clinicians have no definitive information regarding the duration of therapy in patients with the acute coronary disease. The clinical evidence would further clear up future research into strategies for personalized medicine.

Background: Arrhythmogenic cardiomyopathy is electrocardiographically characterized by right precordial T-wave inversions and epsilon waves as major criteria. Additionally, terminal activation delay of 55ms or more serves as a minor criterion. More and more evident are pathological data of right ventricles without dilatation or aneurysm, but typical fibrofatty abnormalities and myocardial atrophy. The ECG’s of these patients lack right precordial T-wave inversion and epsilon waves. Lead aVR and lead V1 could become more and more relevant.

Method: 413 cases with arrhythmogenic cardiomyopathy (292 males, mean age 46.3 ± 11.6 years) and a collective of normal probands (1496 patients, 859 males with an age range of 18-81 years) was analyzed with regard to ECG appearance of lead aVR and the amplitude of inverted T-waves in lead V1.

Results: With a specificity of 99.9%, a positive predictive value of 99.7% and a negative predictive value of 98% lead V1 and aVR were most relevant to diagnose arrhythmogenic cardiomyopathy if an amplitude of Q waves of 3mm or more, R waves of 2mm or less, inverted T waves of 2mm or less in lead aVR and inverted T waves in lead V1 were present.

Conclusion: These two leads appear most relevant to make the diagnosis of arrhythmogenic cardiomyopathy even in cases without right ventricular dilatation and right ventricular aneurysms.

In all the previous research conducted on chylomicrons and their metabolidsm, the potential influence onto the formation and development of atherosclerotic and other changes in the body, the chylomicrons obtained by means of the cannuling of the ductus thoracicus are used exlusively in its abdominal part, immediately from or next to the cisterna chyli. So obtained chylomicrons present essentially a mixture of the particles of various sizes, chemical composition and superficial distribution of the lipid, cholesterol and protein phase, so that their averaged effects are always measured. Chylomicrons obtained from the serum, which are certainly not native chylomicrons, but their remnants, given the proved speed of their decomposition within the circulation. Another extremely important fact has not been researched yet, related to the cannuling of the ductus thoracicus, during which the mixing of chylomicrons with the lymph inflow is permanently disabled, as well as the inflow of chylomicrons and a large part of the lymph into the circulation. Thus, an organism is brought into the state of starvation, which probably leads to changes in the plasma lipoprotein metabolism. Such a situation may also have a retroactive effect on the generation and composition of the newly formed chylomicrons in the small intestine.This fact indicates significant shortcomings in the research of chylomicrons, in defining their potential role and impact on the generation of cardiovascular diseases, since the impact of the lymph and the lymphatic circulation has not been researched. The passage of chylomicrons through the lungs, and the potential impact of mastocytes on their final structure and composition at the moment of their entering the circulatory system has not been researched either. The passage of chylomicrons through ductus thoracicus and lungs can be considered a grey zone, an area which has not been researched yet, and which is to be thoroughly researched. Special attention is to be paid to the generation and role of large chylomicron particles, which I believe are the primary cause of the formation of atherosclerotic, and I hope there will be a research conducted in the future to confirm this.

ARV treatment has improved the quality of life of PHAs, but at the same time the occurrence of complications including the metabolic syndrome.

Objective: To study the prevalence of DM and associated factors in PHAs receiving ARV treatment and follow-up at the University Hospital Center of Borgou (CHUDB) in Parakou in 2016.

Patients and Methods: A cross-sectional, descriptive and analytical study with a prospective collection of data from 1 February to 31 July 2016. A comprehensive recruitment of all PLHIVs of at least 15 years of age was followed at the CHDB and agreed to completion of the study. The metabolic syndrome was defined according to the criteria of the IDF. All patients received a biological check-up.

Results: 215 PHAs were included; the sex ratio was 0.47; the average age: 43.65 ± 11.38 years. The metabolic syndrome was found in 39 patients (18.14%). Among the subjects surveyed, 33.02% were hypertensive. Abdominal obesity, according to IDF criteria was found in 24.19% of cases;the overweight and overall obesity were 28.37% and 09.20%, respectively. Dyslipidemia in 53.95% of cases with total hypercholesterolemia in 32.09% of cases, LDL hypercholesterolemia in 21.86% of cases, HDL hypocholesterolemia in 68.37% of cases and hypertriglyceridemia in 21.86% of cases. Metabolic syndrome was associated with female sex and overweight.

Conclusion: Metabolic syndrome is common in PHAs.